Trevena Inc
NASDAQ:TRVN

Watchlist Manager
Trevena Inc Logo
Trevena Inc
NASDAQ:TRVN
Watchlist
Price: 0.0111 USD 0.91% Market Closed
Market Cap: $9.5k

Operating Margin

-1 525.3%
Current
Declining
by 3 666.1%
vs 3-y average of 2 140.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 525.3%
=
Operating Income
$-57.2m
/
Revenue
$3.8m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 525.3%
=
Operating Income
$-57.2m
/
Revenue
$3.8m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Trevena Inc
NASDAQ:TRVN
9.5k USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 14 112 companies
5th percentile
-1 525.3%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Trevena Inc
Glance View

Market Cap
9.5k USD
Industry
Biotechnology

Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. The company is headquartered in Chesterbrook, Pennsylvania and currently employs 43 full-time employees. The company went IPO on 2014-01-31. The firm is focused on developing and commercializing medicines for patients affected by central nervous system (CNS) disorders. The company is developing OLINVYK, a G-protein biased MOR ligand for acute pain in adults. The company is developing TRV027, an angiotensin II type 1 (AT1), receptor selective agonist, for the treatment of acute lung injury contributing to acute respiratory distress syndrome (ARDS), and abnormal blood clotting in patients with COVID-19. The company is developing TRV250, a G-protein biased delta-opioid receptor (DOR), is developed for the treatment of acute migraine. The firm is focused on exploring other formulations, such as transmucosal or transdermal administration for breakthrough or chronic pain, respectively. The firm is in the Phase III clinical program for OLINVO with the enrollment of patients in the ATHENA study, a Phase III, open-label, multicenter study.

TRVN Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-1 525.3%
=
Operating Income
$-57.2m
/
Revenue
$3.8m
What is Trevena Inc's current Operating Margin?

The current Operating Margin for Trevena Inc is -1 525.3%, which is below its 3-year median of 2 140.7%.

How has Operating Margin changed over time?

Over the last 3 years, Trevena Inc’s Operating Margin has increased from -7 796.9% to -1 525.3%. During this period, it reached a low of -29 580% on Jun 30, 2022 and a high of 14 538.1% on Sep 30, 2022.

Back to Top